BACKGROUND: Fanconi anemia complementation group C and Bloom syndrome, rare autosomal recessive disorders marked by chromosome instability, are especially prevalent in the Ashkenazi* Jewish community. A single predominant mutation for each has been reported in Ahshkenazi Jews: c.711+4A-->T (IVS4 +4 A-->T) in FACC and BLM(Ash) in Bloom syndrome. Individuals affected by either of these syndromes are characterized by susceptibility for developing malignancies, and we questioned whether heterozygote carriers have a similarly increased risk. OBJECTIVES: To estimate the cancer rate among FACC and BLM(Ash) carriers and their families over three previous generations in unselected Ashkenazi Jewish individuals. METHODS: We studied 42 FACC carriers, 28 BLM(Ash) carriers and 43 controls. The control subjects were Ashkenazi Jews participating in our prenatal genetic screening program who tested negative for FACC and BLM(Ash). All subjects filled out a questionnaire regarding their own and a three-generation family history of cancer. The prevalence rates of cancer among relatives of FACC, BLM(Ash) and controls were computed and compared using the chi-square test. RESULTS: In 463 relatives of FACC carriers, 45 malignancies were reported (9.7%) including 10 breast (2.2%) and 13 colon cancers (2.8%). Among 326 relatives of BLM(Ash) carriers there were 30 malignancies (9.2%) including 7 breast (2.1%) and 4 colon cancers (1.2%). Controls consisted of 503 family members with 63 reported malignancies (12.5%) including 11 breast (2.2%) and 11 colon cancers (2.2%). CONCLUSIONS: We found no significantly increased prevalence of malignancies among carriers in at least three generations compared to the controls.
BACKGROUND:Fanconi anemia complementation group C and Bloom syndrome, rare autosomal recessive disorders marked by chromosome instability, are especially prevalent in the Ashkenazi* Jewish community. A single predominant mutation for each has been reported in Ahshkenazi Jews: c.711+4A-->T (IVS4 +4 A-->T) in FACC and BLM(Ash) in Bloom syndrome. Individuals affected by either of these syndromes are characterized by susceptibility for developing malignancies, and we questioned whether heterozygote carriers have a similarly increased risk. OBJECTIVES: To estimate the cancer rate among FACC and BLM(Ash) carriers and their families over three previous generations in unselected Ashkenazi Jewish individuals. METHODS: We studied 42 FACC carriers, 28 BLM(Ash) carriers and 43 controls. The control subjects were Ashkenazi Jews participating in our prenatal genetic screening program who tested negative for FACC and BLM(Ash). All subjects filled out a questionnaire regarding their own and a three-generation family history of cancer. The prevalence rates of cancer among relatives of FACC, BLM(Ash) and controls were computed and compared using the chi-square test. RESULTS: In 463 relatives of FACC carriers, 45 malignancies were reported (9.7%) including 10 breast (2.2%) and 13 colon cancers (2.8%). Among 326 relatives of BLM(Ash) carriers there were 30 malignancies (9.2%) including 7 breast (2.1%) and 4 colon cancers (1.2%). Controls consisted of 503 family members with 63 reported malignancies (12.5%) including 11 breast (2.2%) and 11 colon cancers (2.2%). CONCLUSIONS: We found no significantly increased prevalence of malignancies among carriers in at least three generations compared to the controls.
Authors: Ella R Thompson; Maria A Doyle; Georgina L Ryland; Simone M Rowley; David Y H Choong; Richard W Tothill; Heather Thorne; Daniel R Barnes; Jason Li; Jason Ellul; Gayle K Philip; Yoland C Antill; Paul A James; Alison H Trainer; Gillian Mitchell; Ian G Campbell Journal: PLoS Genet Date: 2012-09-27 Impact factor: 5.917
Authors: Richarda M de Voer; Marc-Manuel Hahn; Arjen R Mensenkamp; Alexander Hoischen; Christian Gilissen; Arjen Henkes; Liesbeth Spruijt; Wendy A van Zelst-Stams; C Marleen Kets; Eugene T Verwiel; Iris D Nagtegaal; Hans K Schackert; Ad Geurts van Kessel; Nicoline Hoogerbrugge; Marjolijn J L Ligtenberg; Roland P Kuiper Journal: Sci Rep Date: 2015-09-11 Impact factor: 4.379
Authors: Richarda M de Voer; Marc-Manuel Hahn; Robbert D A Weren; Arjen R Mensenkamp; Christian Gilissen; Wendy A van Zelst-Stams; Liesbeth Spruijt; C Marleen Kets; Junxiao Zhang; Hanka Venselaar; Lilian Vreede; Nil Schubert; Marloes Tychon; Ronny Derks; Hans K Schackert; Ad Geurts van Kessel; Nicoline Hoogerbrugge; Marjolijn J L Ligtenberg; Roland P Kuiper Journal: PLoS Genet Date: 2016-02-22 Impact factor: 5.917
Authors: Wojciech Kluźniak; Dominika Wokołorczyk; Bogna Rusak; Tomasz Huzarski; Aniruddh Kashyap; Klaudia Stempa; Helena Rudnicka; Anna Jakubowska; Marek Szwiec; Sylwia Morawska; Katarzyna Gliniewicz; Karina Mordak; Małgorzata Stawicka; Joanna Jarkiewicz-Tretyn; Magdalena Cechowska; Paweł Domagała; Tadeusz Dębniak; Marcin Lener; Jacek Gronwald; Jan Lubiński; Steven A Narod; Mohammad R Akbari; Cezary Cybulski Journal: Cancers (Basel) Date: 2019-10-13 Impact factor: 6.639